Viatris Inc. reported first-quarter 2026 financial results with total revenues of $3.5 billion, representing 8% reported growth compared to the first quarter of 2025. Adjusted EBITDA was $1.0 billion, up 10% operationally compared to the first quarter of 2025, demonstrating solid operating leverage.
Key Psychiatric Medication Approvals
In March 2026, Japan’s Ministry of Health, Labour and Welfare approved Effexor SR 37.5 mg / 75 mg capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor, for the treatment of adults with generalized anxiety disorder. This approval represents a key launch for the company in the psychiatric treatment market in Japan.
Overall Performance and Pipeline
The company generated approximately $71 million in new product revenues in the first quarter and continues to expect to deliver approximately $450 million to $550 million in new product revenues in 2026. CEO Scott A. Smith stated that “we delivered a strong first quarter, reflecting disciplined execution across our global businesses” with “continued momentum in key markets like Greater China and North America.”
The company generated U.S. GAAP net cash provided by operating activities of $388 million in the quarter and free cash flow, excluding transaction-related and restructuring costs, of $459 million. Viatris continues to expect more than $2.5 billion of cash available for deployment in 2026, and has reaffirmed its 2026 financial guidance. The company expects to generate between $1.7 billion and $2.0 billion in net cash provided by operating activities for 2026.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.prnewswire.com/news-releases/viatris-reports-first-quarter-2026-financial-results-302765461.html